BTK and B-cell chronic lymphocytic leukemia: BTK inhibitors (BTK = Bruton’s tyrosine kinase) have revolutionized the treatment of B-cell malignancies, particularly chronic lymphocytic leukemia (CLL) and mantle cell lymphoma, with newer-generation agents offering improved safety profiles [6].